A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. - Wikidata - wikimedia - TriplyDB

A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.

A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.

http://www.wikidata.org/entity/Q34412289

about

Clinical Development of the E75 Vaccine in Breast Cancer Novel role of granulocyte-macrophage colony-stimulating factor: antitumor effects through inhibition of epithelial-to-mesenchymal transition in esophageal cancer.Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression.Elevated serum granulocyte-macrophage colony-stimulating factor levels during radiotherapy predict favorable outcomes in lung and esophageal cancer.Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.Breast cancer and immunology: biomarker and therapeutic developments.Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Breast Cancer Immunotherapy: Facts and Hopes.Immunotherapy for breast cancer: past, present, and future.Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.Progress in nonviral gene therapy for breast cancer and what comes next?Immunotherapy of cancers comes of age.Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.Roles for Innate Immunity in Combination Immunotherapies.Immunotherapy for Breast Cancer: What Are We Missing?Revisiting GM-CSF as an adjuvant for therapeutic vaccines.Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.Virus-like particle display of HER2 induces potent anti-cancer responses.Immunotherapy in Breast Cancer: the New Frontier.SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes.

P2860

Q26745440-C9F49F2B-1F77-4DDA-A848-16EE15A773A8 Q33602583-3B332BEB-58D2-4663-88A4-D7838516D4C9 Q35816845-4EA357BC-CCE9-4B5C-ACFC-80D4AA7485C0 Q37554718-2D094244-B3AE-4231-A300-F920E4650116 Q37695311-D27F96EC-A784-4D79-B657-B1A5788DFA67 Q37709102-808604CE-D240-4E1C-945A-BDE07367A1CC Q38293525-269F0989-82DA-4EC3-B2F5-B21F95EB5B90 Q38584383-1988881C-8134-4650-A3F2-DADAF0639850 Q38600417-8CEE67D8-26C9-487F-9DEE-EE0F8F1084BF Q38628198-75B28C1C-293A-47A6-B3A7-E36640F82333 Q38787696-AC728633-B8E3-487C-816C-F43954C4EDE1 Q38896822-7085ABA5-756C-4EBF-B0F1-D61D571FF16F Q39194052-08346253-89DC-4E24-AD6B-B9233EDE6B13 Q40099075-59A4E2EA-3723-485B-8CDC-C0B768512954 Q41593373-2F904AC9-47DC-4A6E-A46C-07F31E3E7523 Q41996352-C66D77E6-6580-4CF9-897B-D95C3A044DCB Q44668850-CFAB4E4E-58AC-44FD-BC66-A97B9C802CE9 Q47604194-0852D3B9-2FF4-4433-941A-B7A315892467 Q48328578-2A22B5A2-FD17-4E7B-8F44-6BFC756C7BC0 Q52699878-2067804F-23DB-4734-8779-6D110CCEF5F3 Q55267620-85CC2524-1AB5-42E5-B9F6-1B6927C9754F Q55342016-56D6271A-0B5D-4C0F-921B-C47BC229EAE8

P2860

A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.

http://www.wikidata.org/entity/Q34412289

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A feasibility study of cycloph ...... ER2+ metastatic breast cancer.

@ast

A feasibility study of cycloph ...... ER2+ metastatic breast cancer.

@en

A feasibility study of cycloph ...... ER2+ metastatic breast cancer.

@nl

type

label

A feasibility study of cycloph ...... ER2+ metastatic breast cancer.

@ast

A feasibility study of cycloph ...... ER2+ metastatic breast cancer.

@en

A feasibility study of cycloph ...... ER2+ metastatic breast cancer.

@nl

prefLabel

A feasibility study of cycloph ...... ER2+ metastatic breast cancer.

@ast

A feasibility study of cycloph ...... ER2+ metastatic breast cancer.

@en

A feasibility study of cycloph ...... ER2+ metastatic breast cancer.

@nl

P1433

Q34412289-635A754A-364F-4B07-9A44-A6C8F89E0B05

P1476

Q34412289-4FF34ED4-A06B-401B-A160-2003F49EFE9C

P2093

Q34412289-0FBA755E-4F23-4538-B9F6-DA2BA389912E

Q34412289-16425B0F-B759-4151-AF72-ECD482312F05

Q34412289-1D0C7EC4-2B03-4663-9843-43142617E0B8

Q34412289-37BCAA4F-D399-4F4F-8CEB-2EA69EC55588

Q34412289-578007F4-940E-49E5-9606-7327704C0362

Q34412289-75BED40F-2E8A-4A67-AC40-80C3071DE04E

Q34412289-797DBABE-5713-47E3-9F40-D129741D699A

Q34412289-81068128-DFA1-4138-AA75-BEDF164C5C0D

Q34412289-81D9C766-0AF5-4655-9458-11FC1D44006E

Q34412289-8B0CE298-ECBE-41BB-AC87-D77DFE397F79

P2860

Q34412289-0B9B8EB2-C288-4886-BFE3-0FE89D198FD6

Q34412289-0FF9A0C7-2315-4B16-89D7-5274D1372ABC

Q34412289-12CF7201-1047-4DC7-A59F-7BD00C4B4729

Q34412289-1BCA9FB9-4319-4BB7-A103-6400789CA806

Q34412289-1C6E7513-3A41-40ED-B437-DB4C4C9C7AE2

Q34412289-1E56E447-CF61-47DA-B7A6-EC31B78193F8

Q34412289-21E96A64-634A-4CE4-A694-42B27C76CC8C

Q34412289-2A743DB6-1314-4CD5-83CE-CB8980888BF9

Q34412289-3A9405FA-DAFC-4D84-AF27-B506E458FF32

Q34412289-3BF74653-14C6-4995-BFC2-6A7390ABAC75

P304

Q34412289-576BB75D-F85D-48B3-8295-105F7D5F26DD

P31

Q34412289-20C877C2-E447-43B7-B140-2F968DD59CB7

P356

Q34412289-E4CA0D5D-6EB6-494B-8CC3-A1175E392B93

P433

Q34412289-944C11BE-A666-41F1-A378-7E7225B5F39F

P478

Q34412289-84E34487-B420-4241-9835-DDB8543C648B

P50

Q34412289-5F15DE20-6503-413A-A823-9BABF14619F0

Q34412289-658290C3-9D8F-4D0D-87E4-8C93C93B5E13

P577

Q34412289-8E4407A9-5005-4C6A-A459-A77891031652

P698

Q34412289-3C2EB0BF-A64F-4C64-A3E4-7FC3718B786B

P921

Q34412289-5F8E598D-1533-41D1-A5BB-20840390BE1F

P932

Q34412289-B3504108-F8F7-4FC8-A92A-367F0A7E4CA1

P356

2326-6066.CIR-14-0058

P1433

Cancer immunology research

P1476

A feasibility study of cycloph ...... ER2+ metastatic breast cancer.

@en

P2093

Antonio C Wolff

http://www.w3.org/2001/XMLSchema#string

Elizabeth Garrett-Mayer

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Duus

http://www.w3.org/2001/XMLSchema#string

Gang Chen

http://www.w3.org/2001/XMLSchema#string

James M Leatherman

http://www.w3.org/2001/XMLSchema#string

Jennifer N Uram

http://www.w3.org/2001/XMLSchema#string

John Fetting

http://www.w3.org/2001/XMLSchema#string

Justin M Asquith

http://www.w3.org/2001/XMLSchema#string

Kellie Hirt

http://www.w3.org/2001/XMLSchema#string

Leisha A Emens

http://www.w3.org/2001/XMLSchema#string

P2860

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

P304

949-961

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-14-0058

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth Jaffee

P577

2014-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25116755

http://www.w3.org/2001/XMLSchema#string

P921

Feasibility study

P932

4211036

http://www.w3.org/2001/XMLSchema#string